NEW YORK – She was 72, and she had injected herself with a compound she found on the internet. When her skin flared up and the irritation did not resolve, she did not know that the substance she had used was not approved by any regulatory body, or that the company whose experimental drug she had obtained had never authorized a single dose outside of a clinical trial. That compound was retatrutide, an obesity medication Eli Lilly is developing and has not brought to market. On Tuesday, Lilly filed six simultaneous lawsuits against the companies selling it anyway.
The filings target six U.S. entities that Eli Lilly accuses of building an illicit supply chain around a drug that exists, so far, only inside a clinical trial. The defendants include pharmacies and peptide vendors that CNBC reported had been selling retatrutide, or compounds marketed under the drug’s name, to consumers without prescriptions, without regulatory oversight, and without any of the safety protocols that clinical trials are designed to provide. Lilly’s chief medical officer described what these vendors are selling as “not a medicine.”
Lilly’s response extends beyond the courthouse. The company said Tuesday it is simultaneously pressing online platforms, payment processors, and federal regulators to close down the market it is pursuing in court. That approach acknowledges what six lawsuits alone cannot accomplish: that the vendors named in Lilly’s filings are part of a supply network larger than six companies, one that has used an arcane regulatory loophole to operate largely in the open for more than a year.
Retatrutide is classified as a triple hormone receptor agonist. It activates three metabolic pathways simultaneously, targeting the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors in a design that produced weight loss in clinical trial participants exceeding results from semaglutide or tirzepatide, the two approved drugs at the center of the obesity treatment market. That data, published in the New England Journal of Medicine and The Lancet, traveled beyond academic journals. It reached patient forums, fitness communities, and social media health channels long before Lilly submitted the drug for regulatory review. Eli Lilly, listed on the New York Stock Exchange as LLY, confirmed the compound remains in Phase 3 clinical trials.
The commercial appetite retatrutide generated before its approval became the foundation of a market that regulators watched grow without intervening to stop it. Online peptide vendors, including a company called Indr Labs, began selling retatrutide under the designation “for research use only,” a label that places products in a regulatory gray zone where sellers have historically avoided pharmaceutical enforcement by claiming the product is not intended for human consumption. By early July, the market had migrated from online storefronts to physical retail: a CBS News correspondent walked into a Brooklyn convenience store and purchased a vial for $95 with no prescription and no questions asked. Following CBS News’ reporting on the retatrutide bodega sales, Indr Labs’ website went password-protected.
The Food and Drug Administration warned in general terms that products sold as research chemicals are “of unknown quality and may be harmful.” No enforcement action targeting retatrutide’s retail distribution had been announced as of Tuesday. That left Lilly’s legal team as the primary institutional check on an illicit market that had reached corner store shelves, creating the unusual situation of a pharmaceutical company going to federal court to protect consumers from a drug it has not yet been permitted to sell.
The “research use only” designation has functioned as a legal shield in many prior proceedings, but Lilly’s filings represent a more direct challenge than regulators have typically mounted against the loophole. A vendor selling a generic research chemical can sometimes claim the product is not a pharmaceutical. A vendor selling a compound marketed specifically as “retatrutide,” a name associated exclusively with Lilly’s clinical program, faces a different argument. Jonathan Darrow, a drug regulation scholar who has taught at Harvard Medical School, told CBS News he was surprised that any company would so openly sell a product lacking FDA authorization. “What argument could they possibly be putting forth to justify this?” he said.
The lawsuits arrive while Lilly manages a separate legal dispute within the GLP-1 market. Novo Nordisk’s lawsuit against Lilly, filed in July, accuses Zepbound’s maker of misleading comparative advertising for its approved tirzepatide product. That dispute is about promotional language and market positioning; the retatrutide action is about the supply chain that emerges around approval delays. Together, the two cases illustrate how a pharmaceutical market projected to exceed $100 billion annually has become legally contested at every stage of the product life cycle, from advertising an approved treatment to suppressing the illegal sale of one still in trials.
The health consequences of the illicit market are not confined to legal filings. America’s Poison Centers has tracked rising toxicity reports linked to retatrutide. Clinical trials screen participants for contraindications, manage doses under medical supervision, and capture adverse events before they become serious injuries. The 72-year-old woman who injected herself operated without any of that structure. The broader pattern has become familiar to poison control staff, who have watched GLP-1 poison control calls rise from fewer than 1,500 annually before 2021 to more than 8,000 by 2023, driven largely by dosing errors with approved drugs. Unapproved compounds add a layer of risk that dosing guidance cannot address, because no dosing guidance exists for them.
The six companies named in Lilly’s lawsuits are not the entirety of the retatrutide black market. The broader vendor network is still operating. The stores where CBS News made its purchases in July remain open. Whether online platforms will remove listings and whether payment processors will close accounts in response to Lilly’s appeals is not yet known. Whether the FDA will follow with enforcement of its own remains similarly unresolved. The company has forced the question into federal court. What regulators, platforms, and the unnamed vendors do next is the part that has no answer yet.
Related Posts
